February 14th Biotech (and Ukraine) Update

I think the market and sector is in a holding pattern until we see what happens with Russia and the Ukraine.  US intelligence indicates an attack this week (with some details indicating a false flag on Tuesday and attack on Wednesday).  If we can get through this week without an attack then perhaps some of […]

Upcoming Phase 3 trials

With a fresh start to 2014 and the biotech market still very strong, we wanted to examine some upcoming Phase 3 results that will be in focus in the first quarter. Expectations for some of these trials varies widely. We have a blend of small biotech to big pharma. Company: Merck (MRK) and Amgen (AMGN) […]

Week’s Option Activity (12/27 ~ 1/9)

The following stocks had notable activity in their options during the past week(s): $GERN (12/27): 663 JUN 5.0 strike Calls (stock at $5.10) were purchased for 1.40 or total cost of $92,820. Buyer makes money if stock trades above $6.40 by June expiration. $CHTP (12/31): 5,500 JAN 4.0 strike Puts (stock at $4.40) were purchased […]